FIELD: biotechnology.
SUBSTANCE: invention relates to engineered natural killer (NK) cells expressing a chimeric receptor, and can be used in medicine for the treatment of cancer expressing natural killer receptor group 2 member D (NKG2D) ligand. The following is proposed: a chimeric receptor that binds NKG2D and contains the following amino acid sequence SEQ ID NO: 109, which includes an NKG2D fragment that binds native NKG2D ligands as an extracellular receptor domain, as well as an effector domain containing CD8a transmembrane domain, OX40 domain, and CD3-zeta. This chimeric receptor may be incorporated into a polypeptide proposed to enhance NK cell cytotoxicity that also contains membrane-bound interleukin 15 (mbIL15) with the following SEQ ID NO: 17.
EFFECT: invention makes it possible to obtain a chimeric receptor capable of transmitting a stimulating signal in an NK cell after binding to native NKG2D ligands, which provides unexpectedly increased cytotoxicity compared to unengineered NK cells.
19 cl, 28 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
